top of page
NIH Brain SPORES Program -

Welcome to the Translational Research Program (TRP)

The Translational Research Program (TRP) is the home of the SPOREs — the Specialized Programs of Research Excellence — a cornerstone of NCI’s efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists working together and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers.


Each SPORE is focused on a specific organ site, such as breast or lung cancer, a group of highly related cancers, such as gastrointestinal cancers and sarcomas, or a common pathway or theme that ties together the cancers under study. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. SPOREs are required to reach a human end-point within the 5-year funding period. Almost 20 organ sites, systems, and pathway-specific themes are represented in the SPORE portfolio, including: bladder, brain, breast, cervical, endometrial, gastrointestinal, head and neck, liver, kidney, leukemia, lung, lymphoma, myeloma, neuroendocrine, ovarian, pancreatic, prostate, sarcoma, and skin.


The program is open to additional organ system or pathway-related translational research, including research in less common cancers. The objective for all SPOREs is to reduce cancer incidence and mortality and to improve survival and quality of life for cancer patients. SPOREs encourage the advice of patient advocates in SPORE activities. Prospective applicants are encouraged to contact TRP Officials for advice prior to submission. The current Program Announcement for submitting applications is

NIH Brain SPORES Program -

  • The Brain Cancer SPORE program was initiated in 2002. Current advances have been made in the treatment of brain tumors and are part of ongoing studies in the Brain Cancer SPORE program, including improved prognostic testing, tumor vaccines, and other immunotherapeutic approaches.  Participating hospitals include:

    Brigham and Women’s Hospital

    Duke University Medical Center

    Northwestern University at Chicago

    University of California, Los Angeles

    University of California, San Francisco

    University of Texas/MD Anderson

bottom of page